SecBot SecBot
8-K ·Filed Oct 26, 2026

VBIO

Valion Bio, Inc.
NEUTRAL
Impact 4/10
Processed4h 32m ago SEC0001437749-26-033460
8-K context-dependent: Items 8.01

Price Chart

Loading chart...

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-033460
Exhibit: ex_1030911.htm0001437749-26-033460
Document: 0001437749-26-033460-index-headers.html0001437749-26-033460
Document: 0001437749-26-033460-index.html0001437749-26-033460
Document: 0001437749-26-033460.txt0001437749-26-033460
19 reports for VBIO
Performance horizon
100% Hit rate @ T+20 3 of 3 directional calls Went positive at some point 7 of 9 best @ T+60▲ +83.75%Jun 18, 2026
Filters
Rows
Reports for VBIO — sortable, filterable
TypeNow
Oct 26, 2026
today
8-K
NEUTRAL ★ 4/10
$1.15awaiting T+20—$0.8098 (−29.33%)
Oct 22, 2026
4d ago
8-K
NEUTRAL ★ 4/10
$0.9560awaiting T+20—$0.8098 (−15.29%)
Oct 21, 2026
5d ago
EFFECT
BEARISH ★ 7/10
$1.12awaiting T+20—$0.8098 (+27.70%)
Oct 21, 2026
5d ago
EFFECT
BEARISH ★ 6/10
$1.12awaiting T+20—$0.8098 (+27.70%)
Oct 16, 2026
9d ago
S-3
BEARISH ★ 6/10
$1.16awaiting T+20—$0.8098 (+30.19%)
Oct 16, 2026
9d ago
DEF 14A
BEARISH ★ 6/10
$1.16awaiting T+20—$0.8098 (+30.19%)
Oct 15, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$1.23awaiting T+20—$0.8098 (−34.16%)
Oct 14, 2026
12d ago
8-K
NEUTRAL ★ 2/10
$1.45awaiting T+20—$0.8098 (−44.15%)
Oct 8, 2026
18d ago
8-K
BEARISH ★ 5/10
$2.21awaiting T+20—$0.8098 (+63.36%)
Oct 7, 2026
18d ago
S-3
BEARISH ★ 7/10
$2.21awaiting T+20—$0.8098 (+63.36%)
Showing 10 of 19

US Market Status

Market Open — Closes in 3h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh VBIO Intelligence

Analysis is for subscribers only.

Valion Bio disclosed that it has received unsolicited acquisition inquiries for its wholly owned CDMO subsidiary, Velocity Bioworks, and has entered preliminary discussions. The company has retained an investment bank to advise on a potential sale, with a key priority being retained manufacturing…

Subscribe for Full Access